Update 2 - The U.S. Food and Drug Administration (FDA) has rejected Capricor's Duchenne muscular dystrophy treatment due to unreliable clinical trial data; the company's shares have plummeted.
路透社2026/11/21 00:11The full text adds detailed information and background.
Reuters, November 21 - The U.S. Food and Drug Administration (FDA) announced on Friday it has refused to approve Capricor Therapeutics’ experimental cell therapy for a deadly genetic disease causing muscle wasting, CAPR.O, adding another regulatory setback for the biotechnology company .
Capricor’s shares fell 77% in after-hours trading, and the company has not immediately responded to Reuters’ request for comment.
Previously, the company had been seeking approval for a therapy called “deramiocel,” aiming to preserve upper limb function in patients with Duchenne muscular dystrophy.
The agency noted there were serious data integrity problems in a key clinical trial, including unauthorized changes to the analysis plan after the start of the trial, breaches of protocols designed to prevent patients and researchers from knowing who received treatment, and other violations of the trial protocol.
The FDA stated these violations “compromised the reliability of the study data.” The agency added that the data were “not considered reliable or interpretable” as evidence and could not demonstrate the therapy’s effectiveness. In addition, the agency noted the therapy failed to meet the primary endpoint of the study.
Duchenne muscular dystrophy is a deadly genetic disorder that mostly affects boys, leading to progressive muscle weakness, loss of mobility, cardiac complications and early death.
This regulatory rejection has dealt a heavy blow to Capricor, threatening its leading experimental asset and casting a shadow over its commercial prospects after months of effort—during which it narrowed its research focus to arm and hand movement in an attempt to rescue the application.
Previously, the FDA advisory committee in July voted 9-3 (link), concluding that the evidence at the time did not corroborate deramiocel’s effectiveness for Duchenne muscular dystrophy-related heart disease.
In August, Capricor submitted a revised application (link), including 24-month data from its late-stage clinical trial and additional analyses, focusing on upper limb muscle function.
(To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translations may contain errors or lack the required context, Reuters does not guarantee their accuracy and provides them solely for reader convenience. Reuters accepts no responsibility for any harm or loss resulting from the use of these automated translations.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
